Long Term Culture Shifts Needed to Sustain CGT Inspection Readiness Understanding the Importance of Inspection Readiness in CGT Facilities Cell and Gene Therapy (CGT) represents a revolutionary approach to treating various diseases, and as its importance grows, so does the scrutiny of regulatory bodies like the U.S. Food and Drug Administration (FDA). Inspection readiness—the state of being prepared for an FDA inspection—is critical for CGT facilities. This involves maintaining compliance with regulations, mitigating potential risks, and addressing common deficiencies identified in FDA inspections. Each CGT facility is required to adhere to stringent guidelines set forth in FDA guidance documents and…

Training SMEs to Present Complex CGT Topics Clearly to Inspectors Training SMEs to Present Complex CGT Topics Clearly to Inspectors In the rapidly evolving field of cell and gene therapy (CGT), ensuring the clarity and efficacy of communication during FDA inspections is crucial. As regulatory, CMC, clinical, and QA leaders work to develop innovative therapies, the ability to present complex scientific topics clearly and effectively is essential to navigate the inspection landscape. This guide aims to equip Subject Matter Experts (SMEs) with the skills necessary for successful interactions with inspectors, thereby enhancing compliance with FDA regulations. Understanding FDA Inspections and…

Digital Tools for Managing Inspection Actions and Evidence Packs in CGT Introduction to FDA Inspections for Cell and Gene Therapy Facilities Cell and gene therapy (CGT) products are transforming therapeutic strategies for a wide range of diseases. Nevertheless, the complexities involved in their development necessitate strict adherence to regulatory requirements set forth by the U.S. Food and Drug Administration (FDA). One significant component of ensuring compliance is preparing for FDA inspections, where investigators assess whether CGT facilities meet Required Current Good Manufacturing Practices (cGMP). This article provides a comprehensive guide on digital tools that can assist CGT professionals in navigating…

Governance for Tracking and Closing CGT Related CAPA After Inspections Cell and gene therapy (CGT) products have the potential to revolutionize treatment paradigms, but they also introduce unique regulatory challenges. Regulatory, CMC, clinical, and QA leaders must navigate a complex landscape of requirements, especially when it comes to compliance and inspection readiness. This tutorial provides a detailed, step-by-step guide on how to effectively manage CAPA (Corrective and Preventive Action) processes following FDA inspections, specifically addressing FDA inspections 483s common deficiencies CGT facilities. Understanding FDA Inspections and 483 Observations The FDA conducts inspections to assess compliance with regulatory requirements, ensuring that…

Global inspection trends for CGT facilities FDA, EMA and MHRA focus areas Global Inspection Trends for CGT Facilities: FDA, EMA, and MHRA Focus Areas Introduction to FDA Inspections for CGT Facilities The increasing complexity of cell and gene therapy (CGT) has led to heightened scrutiny from regulatory agencies, particularly the U.S. Food and Drug Administration (FDA). These inspections are crucial in ensuring the efficacy and safety of CGT products, as well as compliance with current Good Manufacturing Practices (cGMP). As such, understanding FDA inspections, common deficiencies observed, and how to prepare for them is essential for regulatory professionals in this…